Business
AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP
Company to participate in Live Virtual Investor Closing Bell segment today, April 16th at 4:00 PM ET; Register for the event here OCALA, Fla., April 16, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted accelerating momentum in its pancreatic cancer program, underscored by Phase 3 trial planning underway, encouraging Phase 2 clinical signals, and a rapidly strengthening global regulatory and intellectual property (“IP”) position. “The in
About this update from Aim Immunotech Inc.
[{"type":"image","alt":"AIM ImmunoTech Inc.","displaySize":"","headline":null,"caption":"AIM ImmunoTech Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":160,"url":"https://media.zenfs.com/en/globenewswire.com/c64a717b389cb0d8a4c8889b41b5cabd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/KYO5lLNJMwtczbtJGn_KoA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyNA--/https://media.zenfs.com/en/globenewswire.com/c64a717b389cb0d8a4c8889b41b5cabd","width":300,"height":160},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/KYO5lLNJMwtczbtJGn_KoA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyNA--/https://media.zenfs.com/en/globenewswire.com/c64a717b389cb0d8a4c8889b41b5cabd","width":300,"height":160}},"lazy":false},{"type":"text","content":"Company to participate in Live Virtual Investor Closing Bell segment today, April 16th at 4:00 PM ET; Register for the event here","length":134,"tagName":"p"},{"type":"text","content":"OCALA, Fla., April 16, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted accelerating momentum in its pancreatic cancer program, underscored by Phase 3 trial planning underway, encouraging Phase 2 clinical signals, and a rapidly strengthening global regulatory and intellectual property (“IP”) position.","length":367,"tagName":"p"},{"type":"text","content":"“The initiation of Phase 3 planning marks a critical step forward in our mission to bring Ampligen to patients with pancreatic cancer,” said Thomas K. Equels, Chief Executive Officer of AIM. “With a growing body of positive late-stage pancreatic ductal adenocarcinoma clinical data, more than 100 subjects treated, Orphan Drug Designations in the U.S. and EU, and a strong global IP portfolio, we believe Ampligen has the potential to be a game-changing therapy in one of the most lethal cancers and a significant driver of long-term stockholder value.”","length":553,"tagName":"p"},{"type":"text","content":"The Company recently announced a strategic agreement with the PPD™ clinical research business of Thermo Fisher Scientific to design its planned Phase 3 clinical trial of Ampligen® in late-stage pancreatic cancer. This collaboration brings world-class clinical development expertise to support trial design and positions AIM to efficiently advance Ampligen into late-stage development.","length":384,"t...